ICU Medical, Inc. (ICUI)
NEUTRALFondamental
49
Prix
$183.10
Capitalisation boursière
$4.55B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$2.16B
12 derniers mois (au 30/06/2026)
Résultat net
$30M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$92M
Capitaux propres totaux
$2.12B
Passif total
$1.93B
Ratio de liquidité général
2.43
Couverture des intérêts
0.87
Dette/EBITDA
5.28
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$102.68
Prix actuel
$183.10
Marge de sécurité
-78.3%
Fourchette de juste valeur
$66.74 - $138.62
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
153.40
ROE
0.0%
Ratio P/B
2.12
P/FCF
29.87
Marge brute
39.1%
ROIC
1.6%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
1.6%
WACC
8.5%
ROIC − WACC
-6.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (14)
- Gross Margin 39.1%
- P/FCF 29.87
- P/B Ratio 2.12
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Revenue Growth 5Y 11.9%
- Analyst Consensus 92% Buy
- Earnings Surprise avg 20.3%
- Earnings Quality (OCF/NI) 7.86
- Share Dilution 0.1%
- Net Margin Trend 1.4% vs -1.6%
- Piotroski F-Score 7/9
Échoué (12)
- EPS shows upward trend
- EPS CAGR -19.56%
- Price CAGR 2.18%
- ROIC 1.6%
- Operating Margin 3.3%
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 2.2%
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Le nombre d'actions est stable
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Vivek Jain | CEO & Chairman of the Board | 53 |
| Mr. Daniel Woolson | President | 48 |
| Mr. Brian Michael Bonnell | CFO & Treasurer | 51 |
| Mr. Christian B. Voigtlander | Chief Operating Officer | 57 |
| Ms. Virginia Ruth Sanzone | Corporate VP, General Counsel, Secretary & Compliance Officer | 50 |
| Ben Sousa | Chief Information Officer | - |
| Olivia Barrall | Vice President of Human Resources | - |
Risque d'audit
5
Risque du conseil
4
Risque de rémunération
4
Risque droits des actionnaires
5
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for ICUI, sourced from Markets Gazette.